Please assess the completion status of the following clinical trial:

Trial Title: Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must meet all of the following inclusion criteria to be eligible to enroll in this study.~* Patients meeting the criteria for symptomatic multiple myeloma that has relapsed or is refractory to at least 2 prior lines of therapy.~* Previous therapy with bortezomib.~* Previous therapy with thalidomide or lenalidomide.~* Patients must have measurable disease and therefore must have at least one of the following:~Serum M-protein ≥1 gm/dL (≥10 gm/L) Urine M-protein ≥200 mg/24 hr Serum FLC assay: involved FLC ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal.~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to enrollment~* Absolute neutrophil count (ANC) ≥ 1.0 × 109/L within 14 days prior to enrollment Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to enrollment (participants may be receiving red blood cell \[RBC\] transfusions in accordance with institutional guidelines)~* Platelet count ≥ 50 × 109/L (≥ 30 × 109/L if thought to be secondary to myeloma involvement of the bone marrow ) within 14 days prior to enrollment (platelet transfusions are allowed)~* Creatinine clearance (CrCl) ≥ 15 mL/minute within 14 days prior to enrollment, either estimated or calculated using a standard formula (eg, Cockcroft and Gault)~* Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.~* Male participants must agree to practice contraception.~Exclusion Criteria:~* Prior treatment with carfilzomib.~* Known CNS involvement with myeloma~* Pregnant or lactating females~* Major surgery within 21 days prior to registration.~* Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 7 days prior to enrollment~* Known human immunodeficiency virus infection~* Active hepatitis B or C infection~* Unstable angina or myocardial infarction within 4 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless participant has a pacemaker~* Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment.~* Concurrent malignancies, except for treated non-melanoma skin cancer and cervical carcinoma in situ.~* Significant neuropathy (Grades 3-4, ) within 14 days prior to enrollment~* Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)~* Contraindication to any of the required concomitant drugs or supportive treatments, including options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment~* Concurrent therapy with any other anticancer therapeutic with activity against multiple myeloma~* Concurrent therapy with investigative agents (e.g., antibiotics or antiemetics)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carfilzomib (Type: EXPERIMENTAL): A single arm, open-label, single institution phase 2 clinical trial is planned.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete